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Osteoclasts use actin-rich attachment structures in place
of focal adhesions for adherence to bone and non-bone sub-
strates. On glass, osteoclasts generate podosomes, foot-like
processes containing a core of F-actin and regulatory proteins
that undergo high turnover. To facilitate bone resorption, oste-
oclasts generate an actin-rich sealing zone composed of densely
packed podosome-like units. Patterning of both podosomes and
sealing zones is dependent upon an intact microtubule system.
A role for unconventional myosin X (Myo10), which can bind
actin, microtubules, and integrins, was examined in osteoclasts.
Immunolocalization showed Myo10 to be associated with the
outer edges of immature podosome rings and sealing zones, sug-
gesting a possible role in podosome and sealing zone position-
ing. Further, complexes containing both Myo10 and -tubulin
were readily precipitated from osteoclasts lysates. RNAi-medi-
ated suppressionofMyo10 led todecreased cell and sealing zone
perimeter, along with decreased motility and resorptive capac-
ity. Further, siRNA-treated cells could not properly position
podosomes followingmicrotubule disruption.Osteoclasts over-
expressing dominant negative Myo10 microtubule binding
domains (MyTH4) showed a similar phenotype. Conversely,
overexpression of full-lengthMyo10 led to increased formation
of podosome belts alongwith larger sealing zones and enhanced
bone resorptive capacity. These studies suggest that Myo10
plays a role in osteoclast attachment and podosome positioning
by direct linkage of actin to the microtubule network.
Osteoclastic bone resorption is dependent on tight attach-
ment of the cell to the bone substrate. When on bone, oste-
oclasts form the sealing zone, a ring-shaped structure that sur-
rounds the ruffled border, through which protons and
proteases are secreted to effect resorption. Sealing zones are
composed of structural units with certain similarities to podo-
somes that osteoclasts form on non-bone substrates (1). Podo-
somes, termed for their foot-like appearance, are typified by
short F-actin bundles orientated perpendicular to the substrate
(2, 3). Podosomes form a cylindrical core of F-actin with a
“cloud” of microfilaments radiating from the base of the core
(1). Actin-binding proteins, integrins, and regulatory proteins
such as kinases associate specifically with the actin core or the
radiating cloud of F-actin that surrounds the podosomes and
with specific regions of the sealing zone. Microtubules also are
critical for the integrity of these actin-rich structures, as several
groups have demonstrated that podosome and sealing zone for-
mation and function in macrophages and osteoclasts are de-
pendent on an intact microtubule system (4–8).
Myosins are actin-based molecular motors involved in
many cellular processes including muscle contraction, cell
migration, cell polarization, and mitosis. Myosins consist of
a head domain that hydrolyzes ATP and binds F-actin, IQ
domains that bind calmodulin or calmodulin-like proteins,
and tail domains that allow the myosins to attach to cargo.
Categorized by the motor head domain, myosins are currently
grouped into over 20 classes (9). We recently showed that reg-
ulated proteolysis of the “classical” myosin IIA isoform stimu-
lates the onset of cell fusion during osteoclastogenesis (10).
Myosin X (Myo10), which is expressed in most vertebrate tis-
sues at low levels, is the solemember of the classXmyosins (11).
Myo10 possesses a long tail that has been predicted to contain a
coiled-coil domain adjacent to its IQmotifs, allowing dimeriza-
tion as seen with classical myosins (11); however, empirical
studies suggest that this regionmay instead form a single -he-
lix that lengthens the head domain (12). Beyond this region,
each Myo10 tail also possesses three pleckstrin homology
domains (PH), one myosin tail homology 4 domain (MyTH4),2
and a FERM domain (11). PH domains have been shown to be
involved in protein-protein interactions along with mediating
signaling transduction through binding of phosphoinositides
(13). FERM domains link cell membrane proteins to the
cytoskeleton (14), while the less-studiedMyTH4 domains have
been shown to be involved in microtubule binding (15). These
various tail domains allowMyo10 to bind and potentially trans-
port multiple proteins. Myo10, through immunoprecipitation
and hybrid assays, has been shown so far to bind actin, micro-
tubules, VASP, products of PI3 kinase, and beta integrins (16–
19). The importance of microtubule binding toMyo10 recently
has been underscored by several studies demonstrating its role
in assembly and orientation of meiotic and mitotic spindles via
its MyTH4-FERM domains (18, 20, 21).
In this study, we have examined the role of Myo10 in oste-
oclast podosome patterning and sealing zone formation. We
hypothesize Myo10 is a potentially important contributor to
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osteoclast attachment, resorption, and migration due to its
capacity to bind integrins and as an effector of PI3 kinase, a
signaling molecule known to play a crucial role in osteoclast
spreading and motility (22–25). Here we demonstrate that
Myo10 plays a role in osteoclast attachment and subsequent
cell spreading and migration by linking podosomes/sealing
zones to the microtubule network. This work is the first to
define a role forMyo10 in podosome-based adhesion, as well as
demonstrating its role as a linker between the two cytoskeletal
systems in osteoclasts.
EXPERIMENTAL PROCEDURES
Reagents—Affinity-purified chicken antibody against mouse
Myo10 was previously described (26). The specificity of this
antibody in immunocytochemistry is demonstrated in
supplemental Fig. S1, showing lack of reactivity by preim-
mune serum aswell as loss of specific labeling inMyo10 siRNA-
treated cells. In addition, supplemental Fig. S1 shows aWestern
blot of lysate from mature osteoclasts probed with the affinity-
purified antibody. This Western demonstrates that murine
osteoclasts express full-length Myo10 (at 250 kDa), consis-
tent with results seen in macrophages (16). Minor bands repre-
sent breakdown products that are routinely seen in lysates from
osteoclasts, which are highly proteolytically active. A “motor-
less” 165-kDa isoform of Myo10 found in brain (26) is not
detected in osteoclasts. Loading control antibodies to GAPDH
and -actin, both mouse monoclonal antibodies, were pur-
chased from Abcam (Cambridge, MA). A mouse monoclonal
anti--tubulin antibody was purchased from Invitrogen (Carls-
bad, CA).
Cell Culture, Immunocytochemistry, and Microscopy—Oste-
oclasts were generated either from RAW264.7 macrophages
(American Type Culture Collection, Manassas, VA) or murine
bone marrow as previously described (10, 27–29) in the pres-
ence of a soluble form of RANKL (30). For immunocytochem-
istry, osteoclasts were cultured either on glass coverslips or
thinly cut ivory slices and fixed as previously described (10,
27–29). For visualization of microtubules, glutaraldehyde was
added at a final concentration of 0.75% to each fixative solution.
Primary antibodies were added in a standard PEG blocking
buffer, and were detected using Alexa-labeled secondary anti-
bodies (Invitrogen). F-actin was labeled using Alexa-coupled
phalloidin, also from Invitrogen. Nuclei were labeled by incu-
bation with bisbenzimide for 10 min following the secondary
staining. Cells were visualized using either a Nikon Eclipse 80i
epifluorescent microscope with SPOT software (Diagnostic
Instruments, Sterling Heights, MI) or a Zeiss 510 META laser
scanning confocal microscope at the Campus Microscopy and
Imaging Facility, TheOhio State University. Cell perimeter was
measured using SigmaScan Pro 5.0 software (SPSS Science,
Chicago, IL).
Competitive RT-PCR of Myo10 mRNA—To determine
Myo10mRNAexpression levels by competitive RT-PCR, prim-
ers were created that corresponded to murine sequences. The
sense primer was of the sequence 5-AACAATGGACAGCT-
TCTTTCCCG-3, while the antisense primer was of the
sequence 5-GCGATAGCATTCGTTGGCAATGG-3. For an
internal standard, a cDNA was created that corresponded to
the expected PCR product using the primers above, but con-
tained an internal deletion of 21%, a T7 promoter element, and
a tail of 15 adenosines, as previously described (28, 31). This
product was transcribed in vitro using the MAXIscript system
(Ambion, Austin, TX), and 1 pg of the resulting RNA (the inter-
nal standard) was added to 1g of osteoclast total cellular RNA
prior to reverse transcription and PCR. These reactions were
performed using the Superscript First-strand synthesis Sys-
tem and TaqDNA Polymerase, both from Invitrogen. The
resulting RT-PCR products were run in a 2% agarose gel and
stained with ethidium bromide to visualize the relative
intensities of the bands, which were measured using Quan-
tity One software (Bio-Rad).
Immunoprecipitation—Immunoprecipitation was performed
essentially as previously described (10, 32). The cells were sol-
ubilized in M-PER supplemented with protease inhibitors, and
the resulting lysates were centrifuged for 10 min at 20,000  g
to remove insolublematerial. Precleared lysateswere incubated
with Myo10 or tubulin antibody for 12–16 h at 4 °C and then
with anti-chicken IgY-agarose (Gallus Immunotech, Cary, NC)
or protein A-Sepharose for 30min at 4 °C. The complexes were
washed with NET-GEL buffer (50 mM Tris-Cl, pH 7.4, 150 mM
NaCl, 1mMEDTA, 5mM sodium azide, 0.1%Nonidet P-40, and
0.25% gelatin), run in SDS-PAGE, transferred toHybondmem-
brane and probed by Western analysis. [35S]Methionine/cys-
teine pulse-labeling of cells for analysis of Myo10 stability was
performed as previously described (10).
WesternAnalysis—ForWestern analysis of whole cell lysates,
osteoclasts were harvested with M-PER reagent (Pierce Bio-
technology), run in pre-cast PAGE 4–20% gradient gels (Bio-
Rad) and transferred to Hybond membrane (GE HealthCare
Biosciences, Piscataway, NJ). Primary antibodies were allowed
to bind to the membranes using standard methodology, and
were detected using horseradish peroxidase-labeled secondary
antibodies coupled with SuperSignal West Pico Chemilumi-
nescent reagents (Pierce Biotechnology).
RNAi-mediated Knockdown of Myo10—To suppress murine
Myo10 expression, siRNAs were designed and synthesized by
Ambion (Austin, TX). siRNA 73578, which was used for all
relevant experiments, was found to have optimal activity at 75
nM, whereas siRNA 73762, which was used to confirm many of
the results, was optimally active at 50 nM. For all experiments, a
non-targeting dsRNA fromAmbion (Austin, TX) was used as a
negative control, and siRNAs homologous to siRNAs 73578
and 73762 but containing three point mutations in the middle
of the sequence also were used as negative controls (co73578,
co73762). RAW264.7 cells were plated and stimulated with
GST-RANKL to form osteoclasts. On day 4 of differentiation,
targeting siRNAs or an equivalent concentration of a negative
control siRNAwas added to Lipofectamine 2000 (Invitrogen) in
plain Dulbecco’s modified Eagle’s medium and added to the
cells. After 3 h, Dulbecco’smodified Eagle’smediumcontaining
20% fetal bovine serum, L-glutamine, and 100 ng/ml RANKL
were added, and the Lipofectamine complex was allowed to
remain on the cells for 16 additional hours. Using this method,
transfection efficiencies of 95% were achieved, as previously
reported (28). For immunocytochemical analysis, the cells were
scraped and replated on ivory slices or glass coverslips imme-
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diately following the transfection. For RNA analysis, total cel-
lular RNA was harvested 2 days post-transfection with RNA-
Bee (Tel-test, Inc., Friendswood, TX). For protein analysis,
whole cell lysates were harvested 1–4 days post transfection
with M-PER.
Bone marrow-derived osteoclasts were transfected via elec-
troporation as previously described (10, 28, 29). On day 4 of
differentiation in culture, after osteoclasts had formed, cells
were scraped, pelleted, and resuspended in siPORT buffer
(Ambion, Austin, TX). The cells were electroporated at 250
V/50 F with the siRNA solution (75 nM for siRNA 73578, 50
nM for siRNA 73762) or an equal concentration of negative
control siRNA, then plated in standard differentiation medium
on glass or ivory for immunocytochemistry, or plastic for RNA
and protein analysis. As for RAW264.7-derived osteoclasts,
transfection efficiencies were 95%.
Osteoclast Functional Assays—For measurements of bone
resorptive capacity, 3 days post-transfection, osteoclasts were
plated on BD BioCoat Osteologic Discs (BD Biosciences, San
Jose, CA). These discs are composed of calciumphosphatemin-
eral, which is capable of stimulating sealing zone formation in
the absence of protein matrix (33). Control and siRNA-treated
cells were kept on the discs for 3 days. The cells were removed
by the addition of bleach for 5 min and several washes with
water. Resorbed areas (clearings) were assayed by photograph-
ing the resulting discs under lowmagnification, andquantifying
these areas with SigmaScan Pro 5.0 software (SPSS Science,
Chicago, IL) as previously described (10, 28, 29). Equal numbers
of images were compared among test groups. Groups were
assayed for number of clearings, area per clearing, and total
resorption.
Motility was measured by the use of 8.0-m pore Transwell
migration chambers (Corning Life Sciences, Acton, MA). The
bottom side of the membrane was coated with collagen (3
mg/ml diluted 1:2 with 100% ethanol) and dried overnight.
Immediately following the transfection, the cells were scraped
and replated at a low density on the upper side of the chamber.
After 4 days (when RNAi treatment caused Myo10 suppres-
sion), the cells were stimulated to migrate overnight by the
addition of 40 g/ml osteopontin peptide to the bottom of the
well. Cells on the upper side of the membrane were removed
with a cotton swab, and the remaining cells were fixed and
stained for tartrate resistant acid phosphatase using a Leuko-
cyte Acid Phosphatase kit (Sigma).
Microtubule Depolymerization—Osteoclasts 4 days post-
transfection were placed at 4 °C for 3 h. Subsequently, the
chilled medium was replaced with prewarmed (37 °C) medium
for times indicated. Actin podosome belts (defined as a row of
podosomes at the cell periphery) versus podosome clusters and
podosome rings were counted in equal number of frames from
three separate experiments.
Overexpression of Full-length and Myo10 Tail Fragments—
Full-length bovineMyo10 (amino acid residues 1–2052) or var-
ious tail fragments were PCR-amplified from the plasmid GFP-
M10 (34) and subcloned into the pEF6/V5-His expression
vector (Invitrogen). The MyTH4 domain fragment consisted of
amino acid residues 1541–1712, while the MyTH4-FERM
domain fragment consisted of residues 1541–2052. Each were
overexpressed in RAW264.7 cells and selected by 3 g/ml of
blasticidin. For each construct at least four individual clones
were assessed and found to produce similar results.
RESULTS
Myo10 Is Absent from Mature Podosome Belts and Sealing
Zones—Myo10 distribution was visualized by immunocyto-
chemistry in RAW264.7- and mouse bone marrow-derived
osteoclasts plated on glass coverslips or thinly cut ivory. Ini-
tially, we observed Myo10 distribution in osteoclasts that pos-
sessed mature adhesion structures. On glass, these are defined
as peripheral belts of podosomes, a hallmark of fully mature
osteoclasts (4). Myo10 demonstrated a generally diffuse distri-
bution throughout the cytoplasm without specifically overlap-
ping podosomes, but was somewhat enriched immediately
adjacent to peripheral podosome belts, although this enrich-
ment was not present in all cells. Fig. 1A illustrates this distri-
bution in marrow-derived osteoclasts, while Fig. 1B shows a
similar result in RAW264.7-derived cells. Arrows indicate the
enrichment ofMyo10 adjacent to podosome belts. In resorbing
osteoclasts on ivory,Myo10was present throughout the cell yet
was absent from the mature sealing zone (Fig. 1C, single sec-
tions and z-stacks). The general exclusion of Myo10 from
peripheral podosome belts and sealing zones suggest that it is
not a direct component of mature osteoclast adhesion struc-
tures. However, givenMyo10 ability to bind integrins as well as
to mediate effects of PI3 kinase (a signaling molecule with
known effects on osteoclast spreading and migration), we
hypothesized that it might play a role in formation or position-
ing of immature podosome structures and sealing zones. Thus,
its role in osteoclasts was explored further.
Myo10 Is Associated with Maturing Adhesion Structures—
Peripheral belts of podosomes and circular sealing zones are
not generated de novo; their formation occurs through ongoing
processes of podosome or sealing zone patterning (4, 33). Fig.
2A illustrates schematically how podosome belts and sealing
zones are formed from distinct precursor structures. Maturing
osteoclasts, when cultured on a non-bone substrate such as
glass, initially form clusters of podosomes that are dispersed
through the cell interior. As the cells mature, these clusters
become rings that are internal to the cell periphery, until finally
the cell forms a peripheral podosome belt (4). The latter step
from ring to belt is microtubule-dependent, because disruption
of microtubules at this phase inhibits its progression. The for-
mation of sealing zones in bone-attached cells is less well-de-
fined; however, the nascent sealing zone appears to begin as an
actin-rich patch, which then expands into a ring-like structure
(33). However, sealing zone integrity also is dependent on
microtubules, because their disruption causes sealing zone col-
lapse (7, 8).
We examined the distribution of endogenousMyo10 in rela-
tionship to microtubules and/or F-actin in cells that had yet to
formmature podosomebelts or sealing zones. Fig. 2B illustrates
a cell cultured on glass, in the transition stage between a podo-
some ring and the mature belt. The individual and merged
images demonstrate a band of Myo10 overlapping the outer
edges of the podosome ring, with microtubules positioned out-
side but terminating near the Myo10 (arrows). This arrange-
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ment, in which Myo10 is sandwiched between podosomes and
microtubules, was noted in all podosome rings in the process of
transitioning to the belt phase. However, this arrangement of
Myo10 as an intermediary between microfilaments and micro-
tubules was not seen in mature osteoclasts containing podo-
some belts, suggesting that the positioning of Myo10 between
podosomes and microtubules may be a transient event that
occurs during podosome patterning and is no longer needed
once stable podosome belts are formed. Additionally, we
searched osteoclasts cultured on ivory to find nascent sealing
zones in the actin patch stage. When cells were labeled for
Myo10 and F-actin, we found that Myo10 surrounds the actin
patch in a ringed distribution (Fig. 2C). Given Myo10 distribu-
tion in encircling podosome rings andnascent sealing zones, we
hypothesize that this myosin may play a role in patterning of
osteoclast adhesion structures.
Myo10 contains aMyTH4 domain and this domain has been
shown to bind to microtubules (18). Our immunocytochemis-
try suggests that Myo10 may interact with microtubules in
maturing osteoclasts. To examine this by biochemical means,
we immunoprecipitated either Myo10 or -tubulin and West-
ern blotted these precipitates for their potential binding part-
ner. In some cases, immunoprecipitations were performed in
the presence of taxol or phalloidin to stabilize themicrotubules
and microfilaments, respectively. Fig. 2D demonstrates that
FIGURE 1. Distribution of Myo10 in mature osteoclasts. A, mouse bone
marrow-derived osteoclasts were plated on glass and examined by confocal
microscopy for the localization of Myo10 (green) and F-actin (red). Arrows
indicate regions of Myo10 enrichment near the podosome belt. Scale bars, 10
m. B, images of RAW264.7-derived osteoclasts were prepared as in A. C, oste-
oclasts were plated on thinly cut ivory and examined by confocal microscopy
to view Myo10 (green) in relation to the actin ring/sealing zone (F-actin, red).
Myo10 is completely absent in the sealing zone in both RAW264.7 and MBM
derived osteoclasts. Z-stack images of an MBM-derived osteoclast are shown
to illustrate Myo10 distribution throughout the cell. Scale bars, 20 m.
FIGURE 2. Myo10 is positioned between microtubules and actin of form-
ing podosome belts and sealing zone. A, schematic of podosome belt and
sealing zone formation in cultured osteoclasts. B, a marrow-derived oste-
oclast on glass with an immature podosome ring was labeled for Myo10
(green), F-actin (red), and microtubules (blue). Myo10 localizes between F-ac-
tin and microtubules, as shown in the merged image. Scale bars, 10 m. C, a
RAW264.7-derived osteoclast on bone containing a nascent sealing zone
(actin patch) was labeled for Myo10 (green) and F-actin (red). Myo10 is present
in a ring at the perimeter of the actin patch. Scale bar, 10 m. D, Myo10 or
-tubulin was immunoprecipitated from maturing RAW264.7 osteoclasts and
the resulting precipitates were Western blotted for the same proteins. Under
all conditions, co-precipitation of -tubulin and Myo10 was noted. In the last
lane, immunoprecipitations were performed with MOPC-21, an irrelevant
mouse IgG control antibody.
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under all conditions tested, Myo10 and -tubulin were able to
co-precipitate. These results, coupled with the immunochem-
istry shown in Fig. 2B, indicate that Myo10 may act as a linker
between the microfilament and microtubule arms of the
cytoskeleton in osteoclasts.
RNAi-mediated Myo10 Suppression Causes Decreased Seal-
ing Zone Perimeter, Resorption, Cell Spreading, and Motility—
To examine the function of Myo10 in osteoclasts, RNA in-
terference was used to suppress Myo10 expression in both
RAW264.7- and mouse bone marrow-derived osteoclasts. In
Fig. 3A, targeting and negative control siRNAswere transfected
on day 4 of osteoclast differentiation and assayed for Myo10
mRNA levels 2 days post-transfection. Three negative control
double-stranded oligonucleotides failed to decrease the levels
of Myo10 mRNA in RAW264.7 osteoclasts while both siRNA
73578 and 73762 decreased the mRNA expression by 90%
(n  3) when measured by competitive RT-PCR (Fig. 3A, top
panel). Four days post-transfection in RAW264.7 osteoclasts,
Myo10 protein levels were reduced to 62.0  4.5% (siRNA
73578) or 44.2  5.6% (siRNA 73782) of control levels (n  3;
Fig. 3A,middle panel). Similar efficiencies of knockdown were
achieved in mouse marrow-derived osteoclasts (Fig. 3B). To
further explore the timing of Myo10 suppression, control- or
siRNA-treated cells were examined over a 4-day period. Fig. 3C
shows an example of a Western blot in which the timing of
suppression was assessed, whereas Fig. 3D presents a graphical
compilation of multiple such experiments. As shown, modest
levels of protein knockdownwere achieved early post-transfec-
tion, but were substantial at day 4. This lag in suppression was
suggestive of slow turnover kinetics of the Myo10 protein.
However, previous reports have indicated a rapid turnover
(2–2.5 h) for transfectedMyo10 inHeLa cells (35, 36). To deter-
mine whether Myo10 demonstrates a greater stability in our
cultures, pulse-chase analysis was performed onwild-type oste-
oclasts. Cells were pulse-labeled with [35S]methionine/cysteine
and Myo10 was immunoprecipitated from cell lysates after
varying times in medium lacking radiolabel. As shown in Fig.
3E, Myo10 demonstrated great stability in osteoclasts, as even
after 48 h of chase, 80% of the originally labeledMyo10 protein
remained. Extrapolation from these data predicted a half-life
of 4.7 days. This result is generally consistent with our find-
ing that siRNA treatments resulted in 45–65% knockdown
at 4 days post-transfection. Therefore, for all subsequent
experiments with siRNA-treated osteoclasts, cells were
examined on day 4 post-transfection when Myo10 protein
levels were at their lowest.
siRNA-treated osteoclasts on ivory were examined by label-
ing with fluorescent phalloidin to determine changes in the
sealing zone. In both RAW264.7 and mouse bone marrow-
derived osteoclasts, the major change seen was a decrease in
the perimeter of the sealing zone compared with controls.
Fig. 4A, left, shows representative sealing zones from con-
trol- and siRNA-treated cells, each containing 5 nuclei and
photographed at the same magnification. Sealing zone perime-
ters were measured in multiple cells and found to decrease by
forty percent while no overall change in nuclear number was
seen (Fig. 4A, graphs). Thus, suppression of Myo10 causes
decreased sealing zone perimeter without affecting cell fusion.
Although only one control is shown in this figure, subsequent
experiments were performed comparing all three siRNA con-
trols, which gave identical results (data not shown).
siRNA-treated osteoclasts on glass were labeledwith fluores-
cent phalloidin to determine podosome structure and cell
spreading. Whereas the siRNA-treated cells were capable of
generating podosomes, they exhibited a readily noticeable dif-
ference in cell size when compared with controls. As shown in
Fig. 4B, siRNA-treated cells possessed a cell perimeter similar
to that of control cells over the first 3 days post-transfection,
but were noticeably diminished in perimeter, to about 60% of
controls, on day 4 when Myo10 protein expression was at its
lowest (refer to Fig. 3D). These results show a direct correlation
between levels of Myo10 protein expression and osteoclast
FIGURE 3. Suppression of Myo10 in osteoclasts. A, competitive RT-PCR and
Western analysis of RAW264.7-derived osteoclasts. siRNAs 73762 and 73578
decreased Myo10 mRNA expression, whereas three negative controls (con-
trol, a generic non-targeting double-stranded RNA oligonucleotide;
mut73762 and mut73578, mutant versions of 73762 and 73578) did not affect
Myo10 expression. mRNA was measured 2 days post-transfection. Protein
levels measured by Western analysis 4 days post transfection also demon-
strate siRNA-specific loss of Myo10 while exhibiting no change in any of the
controls. -Actin levels did not change. B, competitive RT-PCR and Western
analysis of marrow-derived osteoclasts. SiRNAs 73762 and 73578 elicited spe-
cific knockdown of Myo10, similar to that seen in RAW264.7-derived cells.
C, Western analysis shows time course of Myo10 protein expression following
transfection of siRNA 73578 into marrow-derived osteoclasts. The control
used was a non-targeting RNA oligonucleotide. D, multiple experiments like
those in panel C were quantified and graphed to show mean expression 
S.D. relative to control transfectants (n  3). E, wild-type osteoclasts were
pulse labeled with [35S]methionine/cysteine for 2 h, followed by chases of
0, 1, 2, 24, and 48 h. Myo10 was immunoprecipitated from samples
adjusted to equivalent numbers of cpm. Results shown are the averages of
4 experiments  S.D.
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perimeter. When average cell perimeter was measured on day
4, the resulting perimeters for both RAW264.7- and marrow-
derived osteoclasts treated with siRNA 73578 were about sixty
percent of the control (Fig. 4C). Although only one control is
shown in this figure, subsequent experiments were performed
comparing all three siRNA controls, which gave identical
results (data not shown). Again, no differences in nuclear num-
ber were caused by Myo10 knockdown. This indicates that the
changes in cell perimeter and sealing zone perimeter are not
due to changes in the level of cell fusion. siRNA 73762 gave
qualitatively similar results, as demonstrated in supplemental
Fig. S2, A and B.
Because Myo10 knockdown caused changes in both seal-
ing zone and cell spreading, we assessed functional changes
by resorption and migration assays. First, osteoclasts treated
with control or Myo10 siRNAs were plated on synthetic bone
substrate for 3 days to allow for resorption. The clearing size
and number of clearings along with
total resorbed area was measured.
We found that Myo10 siRNA-
treated osteoclasts resorbed less in
all measurements (Fig. 4D). In addi-
tion to defects in resorption, the
motility of cells treated with siRNA
73578 was diminished when exam-
ined in Transwell migration assays.
When stimulated to undergo direc-
tional migration by addition of
osteopontin to the underside of
Transwell filters, siRNA-treated
osteoclasts (either RAW264.7- or
marrow-derived) demonstrated lev-
els of migration only 40% of that of
controls (Fig. 4E). Similar results
were achieved with siRNA 73762, as
shown in supplemental Fig. S2C.
RNAi-mediated Myo10 Suppres-
sion Inhibits Microtubule-dependent
Podosome Belt Formation—As de-
scribed above, podosome belt po-
sitioning at the cell periphery in
macrophages and osteoclasts is de-
pendent on intact microtubules
(4–6). When microtubules of
mature osteoclasts are disrupted,
the podosome belt collapses, but
recovers by transitioning through
the podosome cluster and ring
stages before reforming the belt.
Thus, disruption of microtubules
recapitulates the formation of
podosome belts seen in maturing
osteoclasts. Because Myo10 inter-
acts with microtubules in oste-
oclasts, we transiently depolymer-
ized microtubules in these cells and
assessed how Myo10 suppression
affected podosome repositioning.
Control- and siRNA-treated cells were placed at 4 °C for 3 h,
which caused complete disruption of the microtubule network
and a collapse of the podosome belt. The initial 3-h cold treat-
ment caused all cells to be devoid of amicrotubule network or a
podosome belt in both the control- and siRNA-treated cells
without detachment of the cells (Fig. 5A, top panels). After 24 h
of recovery, microtubule networks were regenerated. Whereas
control cells re-formedmature podosome belts, siRNA-treated
cells organized their podosomes in internal clusters or small
rings (Fig. 5A). This can be seen in a low magnification view of
both control- and siRNA-treated cells after 24 h recovery (Fig.
5B). Almost 100% of the control cells recovered their peripheral
podosome belts after 24 h, while less than 3% of siRNA-treated
cells did so (Fig. 5B, graph). Thus, the defect in Myo10-sup-
pressed cells appears to be in podosome patterning and not
formation, asMyo10 siRNA-treated cells were capable of form-
ing podosomes, but did not localize them correctly. Because
FIGURE 4. Myo10 suppression leads to a decrease in cell and sealing zone spreading. A, 4 days post
transfection, osteoclasts treated with a control non-targeting oligonucleotide or siRNA 73578 were fixed and
stained with phalloidin. Confocal images demonstrate the decrease in sealing zone perimeter resulting from
Myo10 suppression. Both control and siRNA-treated cells depicted have 5 nuclei. Scale bars, 10 m. Graph
represents mean relative sealing zone perimeter  S.D. or nuclear number  S.D.; n  62 for RAW264.7 cells
and n  45 for mouse bone marrow (MBM) cells from three separate experiments. B, confocal images demon-
strate the decrease in cell perimeter resulting from Myo10 suppression. Scale bar, 50 m. siRNA treatment of
RAW264.7 and mouse bone marrow-derived osteoclasts resulted in decreased perimeter 4 days post-transfec-
tion. Data points indicate mean relative perimeter  S.D. of at least 50 cells. C, osteoclast perimeter and nuclear
number were quantified for control- and siRNA 73578-treated cells 4 days post-transfection. Bars represent
mean relative perimeter or nuclear number  S.D.; n  42 for RAW264.7 cells and n  32 for MBM cells.
D, resorptive capacity of control- versus siRNA 73578-treated cells was compared using synthetic bone sub-
strate. Myo10 suppression decreased the number and size of clearings leading to a decrease in total resorption.
Bars represent mean resorption  S.D. for three separate experiments. E, osteopontin-directed motility was
measured in both RAW264.7 and MBM osteoclasts by Transwell migration assays. Myo10 suppression by siRNA
73578 resulted in loss of motility in both cell types. Bars represent mean relative motility  S.D. for three
separate experiments in which at least 390 cells were assayed for each sample.
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siRNA-treated cells were capable of re-forming microtubules
following their disruption but could not position podosomes in
a microtubule-dependent manner, these results further suggest
that Myo10 might act as a link between podosomes and micro-
tubules. However, previous studies by others have shown that
the accumulation of stable microtubules in mature osteoclasts
is dependent on the small GTPase Rho (37). To determine
whether Rho activity might be altered in Myo10-suppressed
cells, we assayed levels of active Rho in control- or siRNA-
treated cells. Rho activity was unaltered, as was activity of the
related GTPase Rac (data not shown).
Overexpression of MyTH4-containing Tail Fragments
Inhibits PodosomeBelt and SealingZone Formation—Todelin-
eate regions of Myo10 potentially involved in podosome pat-
terning, and to support the emerging hypothesis that Myo10
links podosomes tomicrotubules during patterning of adhesion
structures, we created plasmid constructs that contained vari-
ous Myo10 tail domains alone or in combination in the pEF6/
V5-His expression vector (Fig. 6A). These constructs, in addi-
tion to an empty vector for control, were transfected in
RAW264.7 cells to generate stably transfected clones that over-
expressed each domain. The cells were then differentiated into
osteoclasts and labeled with phalloidin to visualize the F-actin
podosome structures and general cellmorphology. At least four
clones for each construct were examined; all produced similar
results. Previous studies have used overexpression of truncated
Myo10 tail domains for dominant negative inhibition ofMyo10
function (16, 18, 38). Because MyTH4 is the minimal microtu-
bule binding domain of Myo10 and the combination of
MyTH4-FERM is more efficient at binding microtubules than
the MyTH4 domain alone, we
examined the podosome pheno-
types of control and MyTH4 or
MyTH4-FERMoverexpression cells
on glass (15, 18). MyTH4- and
MyTH4-FERM-overexpressing os-
teoclasts were unable to form podo-
some belts, but instead formed
internal rings and clusters (Fig. 6B,
top row). This effect was particularly
notable in cells expressing MyTH4-
FERM domains. To be sure this was
not a differentiation-dependent
patterning effect, microtubules in
mature osteoclasts overexpressing
MyTH4 or MyTH4-FERM were
depolymerized by cold treatment,
and cells were allowed to recover
overnight.MyTH4-expressing oste-
oclasts, like siRNA-treated cells,
could not recover podosome belts
and were inhibited from transition-
ing out of the internal ring stage.
MyTH4-FERM-expressing oste-
oclasts were evenmore affected and
could generate only very small
podosome rings (Fig. 6B, middle
row). Further, these cells made poor
sealing zones when cultured on ivory. While MyTH4-express-
ing cells were capable of making small sealing zones, MyTH4-
FERM-expressing cells primarily formed actin patches, remi-
niscent of those preceding sealing zone formation (Fig. 6B,
bottom row).
Overexpression of Full-length Myo10 Leads to Increased
Podosome Belt and Sealing Zone Formation—To reaffirm the
role of Myo10 in podosome positioning and formation of the
sealing zone, full-length Myo10 was cloned into the pEF6/V5-
His expression vector and stably overexpressed in RAW264.7
cells. The empty vector was used as a control for these studies.
We noted that RAW264.7 cells could not readily tolerate long-
term overexpression of the full-length myosin. Of three exper-
iments where 12 individual clones were chosen for expansion
each time, only two clones (FLX1 and FLX2) survived to pro-
duce enough cells for further study. By Western, the Myo10
band intensities of FLX1 and FLX2 increased to 140 1.3% and
199  3.5% of control cells, respectively (data not shown). The
pEF/V5-His vector uses the human elongation factor-1 pro-
moter to keep overexpression levels low compared with more
commonly used viral promoters, but even under these condi-
tions, RAW264.7 cells apparently tolerate long-term overex-
pression of Myo10 poorly.
The resulting clones were plated on glass and the F-actin
phenotype was examined by labeling with fluorescent phal-
loidin. Initially, undifferentiated RAW264.7 macrophages
were examined (Fig. 7A, top panels). Whereas control trans-
fectants exhibited normal F-actin distribution, clones FLX1
and FLX2 generated distinct podosome belts, a phenotype
normally present only in osteoclasts. When the clones were
FIGURE 5. Suppression of Myo10 leads to an inability to regenerate podosome belts after microtubule
depolymerization. A, osteoclasts at 4 days post-transfection with non-targeting control or targeting siRNA
73578 were cold-treated to depolymerize microtubules, and allowed to recover for 0 or 24 h at 37 °C. Cells
plated on glass were viewed by confocal microscopy after fixation and labeling for microtubules (red) and
F-actin (green). Control cells recovered peripheral podosome belts 24 h following microtubule disruption, but
siRNA-treated cells did not. Scale bars, 20 m. B, low magnification confocal photomicrographs of cells recov-
ered for 24 h demonstrate the differences in podosome distribution between control- and siRNA-treated cells.
Scale bars, 30 m. Graphical representation of the proportion of cells exhibiting a podosomal belt versus
podosome clusters/rings. Bars represent the mean  S.D. of three experiments, in which at least 350 cells were
assayed for each experiment.
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differentiated into osteoclasts, control cells generated typi-
cal podosome belts, but the podosomes of FLX1 and FLX2
were arranged in unusual conformations (Fig. 7A, bottom
panels). Myo10-overexpressing cells produced podosomes
in multiple ring and belt structures. Higher magnification of
one of these cells demonstrates the appearance of intensely
labeled belts with multiple internal rows of podosomes (Fig.
7B). Perimeter and nuclear number was measured for these
cells and both were found increase when Myo10 was overex-
pressed (Fig. 7B, graph). When cells overexpressing Myo10
were cultured on ivory and stained with fluorescent phalloi-
din to visualize the sealing zone, sealing zone perimeter was
increased (Fig. 7C; note differences in scale of photos and
associated graph), leading to cells with greater resorptive
capacity (Fig. 7D). Thus, while suppression of Myo10 func-
tion by either RNA interference or dominant negative inhi-
bition by the MyTH4 domain inhibited podosome belt for-
mation and sealing zone spreading, overexpression of the
full-lengthMyo10 forced an increase in peripheral and inter-
nal podosome patterning and sealing zone spreading. These
results and those previously described clearly indicate a role
for Myo10 in regulating adhesion structure patterning
through a microtubule-dependent process.
DISCUSSION
The relatively recently described class X myosin was first
characterized as the founding member of a group of myosins
containing MyTH4, FERM, and multiple pleckstrin homol-
ogy domains (11). In other cell types, Myo10 has been shown
to be involved in producing protrusions at the cell mem-
brane as it plays a role in filopodia extensions (35, 38) and
axonal guidance (39) and is found to localize in lamellipodia
(11) and phagocytic cups (16). Podosomes and sealing zones
FIGURE 6. Overexpression of the MyTH4 domain suppresses podosome
belt and sealing zone formation. A, diagram of Myo10 tail domain clones
used in this figure. Each was stably overexpressed in multiple RAW264.7 mac-
rophage clones and differentiated into osteoclasts. B, osteoclasts overex-
pressing the MyTH4 and MyTH4-FERM domains were labeled with fluores-
cent phalloidin to visualize F-actin, revealing that dominant negative
overexpression of Myo10 tail domains caused the cells to be unable to form
podosome belts under normal growth conditions (top row) or after microtu-
bule depolymerization (middle row). Further, these cells formed only small









































































FIGURE 7. Overexpression of full-length Myo10 promotes formation of
adhesion structures. A, full-length Myo10 was stably overexpressed in
RAW264.7 macrophages. FLX1 and FLX2 refer to individual clonal lines trans-
fected with the full-length Myo10 while control cells were transfected with
empty vector. Overexpression of full-length Myo10 promoted podosome
belt formation in macrophages as indicated by fluorescent phalloidin label-
ing (top panels). In osteoclasts differentiated from the transfected clonal lines,
overexpression of Myo10 induced excessive formation of podosome belts
and rings (bottom panels). Scale bars, 50 m. B, (left) a high magnification view
of a single mature osteoclast overexpressing Myo10 illustrates excessive
podosome belt and ring formation (left panel). Scale bar, 20 m (right). Cells
overexpressing Myo10 show greater cell size and nuclear number than con-
trols. Bars represent mean relative cell perimeter and nuclear number  S.D.
C, (left) Myo10 overexpressing cells were plated on thinly cut ivory, and F-ac-
tin was visualized to demonstrate the relative sizes of sealing zones. Scale
bars, 10 m, (right) quantification of sealing zone perimeter represents mean
relative  S.D. D, Myo10-overexpressing cells were plated on synthetic bone
substrate for 3 days, and resorptive capacity was measured. Quantification
represents mean of three experiments  S.D.
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are actin-based structures that interact with, and are depen-
dent on, intact microtubules for formation and function.
Whereas a few proteins have been proposed to link the podo-
some and microtubule networks, Myo10 is the first potential
linker known to directly bind both actin and microtubules.
The data presented here suggest a model in which a ring
of Myo10 encircles immature podosome rings or nascent
sealing zones, and through interaction with microtubules,
provides force to drive expansion of these adhesion struc-
tures into peripheral podosome belts and mature (i.e. fully
expanded) circular sealing zones. As demonstrated above,
loss of Myo10 function through siRNA-mediated knock-
down resulted in smaller sealing zones and poor cellular
spreading; these defects not surprisingly negatively influ-
enced cell capacities for motility and bone resorption. Fur-
ther, overexpression of dominant negative tail fragments
carrying the MyTH4 domain also inhibited podosome belt
and sealing zone formation. This finding, along with the fail-
ure to properly pattern podosomes after microtubule depo-
lymerization, suggests that Myo10 does indeed act as a linker
between podosomes and microtubules. We also demon-
strated that endogenous Myo10 has very slow turnover
kinetics in osteoclasts, with a predicted half-life in excess of
4 days. This is in contrast to findings in HeLa cells, in which
transfected GFP-Myo10 was shown to possess a half-life of
2–2.5 h (36). This finding illustrates that regulation of
Myo10 stability can be markedly different in different situa-
tions. It further suggests that whereas Myo10 may play tran-
sitory roles in some cell types, its ongoing presence is
required in osteoclasts for continuous formation and rear-
rangement of the bone resorptive apparatus.
Previous studies have suggested roles for other proteins in
mediating linkage between microtubules and podosomes.
Linder et al. (6) suggested a role for the actin-binding protein
WASP in mediating podosome to microtubule interaction
through a second intermediate, CIP4 (CDC42-interacting
protein 4). TheWASP polyproline domain that binds CIP4, a
microtubule binding protein, was found to block podosome
regeneration without affecting the microtubule network
when injected into macrophages (6). Perhaps relevant to
these findings, Myo10 has been proposed to interact with
and transport VASP, a WASP related protein that shares
similar structural motifs such as the polyproline domain, to
the tip of filopodia (17). A second protein, kinesin KIF1C,
also has been proposed as the microtubule-podosome link
(41). Again, it was suggested that KIF1C binds microtubules
and a second intermediate binds actin. Immunoprecipita-
tion of KIF1C from HUVECs resulted in co-precipitation of
nonmuscle myosin IIA, which was purported to directly
interact with KIF1C, although conditions by which these
experiments were performed may have resulted in precipita-
tion of indirectly bound actin-associated proteins. Although
Kopp et al. (10) found that pharmacological inhibition of non-
muscle myosin IIA inmacrophages via blebbistatin (which also
inhibits macrophage myosin IIB) decreases podosome forma-
tion, our own studies in osteoclasts demonstrated that specific
inhibition of myoIIA via RNA interference did not affect podo-
some formation. Nonetheless, multiple linker proteins may be
responsible for microtubule regulation of podosome/sealing
zone function, and the results here indicate that Myo10 may
mediate this connection via its microtubule-binding MyTH4
tail domain specifically in transitions tomature podosome belts
and sealing zones. Unfortunately, we were unable to utilize
video live cell imaging to followMyo10 trafficking in podosome
positioning/sealing zone formation. As described in Fig. 7, oste-
oclasts tolerate overexpression of Myo10 very poorly, and the
obligatory low levels of fluorescently tagged myosin that we
were able to achieve did not allow for proper visualization.
Myo10 may be playing additional roles in osteoclasts
beyond podosome/sealing zone patterning. Although recent
evidence suggests many PH domains are utilized for protein-
protein interaction, the Myo10 PH also domains have been
shown to bind PI3 kinase products (42). GFP-tagged Myo10
PH domains bind the plasma membrane of mouse myoblasts
(43), and Myo10 is recruited to the phagocytic cups of mac-
rophages in a PI3-kinase-dependent manner (16). Prelimi-
nary experiments using Myo10 PH domains as a dominant
negative suggest a role in podosome formation (not shown).
Myo10 also has been shown to bind beta integrins via the
FERM domain (19). Both PI3-kinase signal transduction and
integrin-mediated signaling and attachment play roles in
proper osteoclast function (22, 44, 45). Studies are on-going
to better examine potential relationships between these
activities and Myo10 function. Additionally, a recent study
demonstrated that the bone morphogenetic protein BMP6
induces Myo10 expression in endothelial cells and Myo10 is
required to guide migration of these cells toward BMP6 gra-
dients (46). Although the effects of BMPs on osteoclast activ-
ity is poorly understood, a number of studies have suggested
a role for these proteins in promoting osteoclast recruitment
and activity (40, 47–50). It will be of interest to determine if
BMPs play a role similar to that in endothelial cells by regu-
lating osteoclastic Myo10 expression, motility, and poten-
tially resorption.
In summary, these studies reveal several novel aspects of
Myo10 function in mammalian cells. While previous reports
demonstrated that this motor protein linked actin- and micro-
tubule networks during spindle formation (18, 20, 21), this
study illustrates that this linkage is of import to mammalian
cells in regulating adhesion and motility. The presence of
MyTH4 domains in actin-based motor proteins is particularly
gratifying in that it suggests that these myosins act as direct
linkers between the cytoskeletal networks without a require-
ment for other protein intermediates. Given the presence of
microtubule binding domains inMyo10, it is tempting to spec-
ulate that this motor protein may serve to link actin andmicro-
tubules for a number of cellular processes. The current study
demonstrates a central role for Myo10 in positioning of adhe-
sion complexes, at least in those cells like osteoclasts, where
adhesion is mediated by podosome-based structures. Of con-
tinued interest will be the functions of the FERM and PH
domains ofMyo10 in osteoclast activity, as well asMyo10 over-
all role in potential regulation of the bone resorptive process
through PI3K, integrin, BMP, and binding partners yet to be
determined.
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